4-Pyridylboronic Acidum CAS 1692-15-5 Puritas ≥99.5% (HPLC) Factory Hot Sale
Manufacturer Supple, Puritas, Commercial Productio
Nomen chemicum: 4-pyridylboronic acidumCAS: 1692-15-5
| Nomen chemicum | 4-Pyridylboronic Acid |
| Synonyma | Pyridine-4-Boronic Acid |
| CAS Number | 1692-15-5 |
| CATTUS Number | RF-PI571 |
| Stock Status | In Stock, Productio Capacity 25 Tons/mense |
| Formulae hypotheticae | C5H6BNO2 |
| M. Pondus | 122.92 |
| Solubilitas | Insolubilis in aqua |
| Liquescens punctum | >300℃ (lit.) |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba pulveris |
| Puritas / Analysis Methodus | >99.5% (HPLC) |
| Humor (auctore Karl Fischer) | <0.50% |
| una immunditia | <0.50% |
| Totalis immunditias | <0.50% |
| Metalla gravia (ut Pb) | <20ppm |
| Test Standard | Enterprise Standard |
| Consuetudinem | Pharmaceutical intermedia |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.
4-Acid pyridylboronicum (CAS: 1692-15-5) adhiberi potest ut candidatus reactionis coniunctionis Suzuki-Miyaura.Praesertim, ut in N-continens caudices aedificium, acidum pyridium-4-boronicum adhibitum est ad componendas aliquas compositiones heterocyclicas cum actionibus biologicis superioribus.4-Acid pyridylboronicum est genus Acidum boronicum derivativum.Utile aedificium est in crystallo machinarum caudices.Potest etiam uti catalysts ad agendum ut agens condensationem dehydrativam ad componendum amidum utendo acido carboxylico et amine ut materia rudis.Eius derivativum, polystyrenum acidum 4-pyridineboronicum ligatum, catalysta utilis est ad reactionem amidationum ac estimationem acidorum alpha-hydrocarboxylicorum.
Reagens ad usum: Palladium-catalyzed Suzuki-Miyaura motus copulationis;Ligand-liberum palladium-catalyticum Suzuki reactionem copulationis sub proin irradatione;Reagens usus est in: Praeparatio inhibitores HIV-1 protease;Cancer potentialis threapeuticus, ut PDK1 et interdum kinasus CK2 inhibitores.
